Background
The worldwide development of antimicrobial resistance in Neisseria gonorrhoeae is a serious problem for treatment and control of gonorrhoea. Numerous formerly effective antibiotic agents are no longer useful for the therapy of gonorrhoea. High-level penicillin resistance and quinolone resistance have disseminated globally. Third generation cephalosporins are amongst the last agents to remain effective. But reduced susceptibility to third generation cephalosporins is increasingly observable. As gonorrhoea is no longer a reportable disease in Germany, we implemented a new antimicrobial resistance (AMR) surveillance system and present first data.
Methods
We performed annually (2010-2012) a non-selected continuous collection of Neisseria gonorrhoeae isolates from all regions of Germany to monitor the antimicrobial resistance to a range of therapeutically relevant antimicrobials: cefixime, ceftriaxone, azithromycin, spectinomycin, ciprofloxacin and penicillin. All isolates were tested in London. Susceptibility data were submitted to the European Gonococcal Antimicrobial Surveillance Programme (EURO-GASP) of the European Centre for Disease Prevention and Control (ECDC). Rates of ciprofloxacin (51-74%) and high-level plasmid-mediated penicillin resistance (PPNG, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) are high across Germany (Figure 1 ) Azithromycin resistance ranged from 1-8%. No resistance to spectinomycin or cephalosporins was observed.
Results
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Conclusion
Cefixime is no longer recommended as first line therapeutic agent against gonorrhoea due to the high number of isolates with reduced susceptibility. Ceftriaxone is still an appropriate treatment for gonorrhea in Germany, but a drift to decreased susceptibility can be observed (Figure 2 ). Azithromycin remains still effective against gonorrhoea. Rates of ciprofloxacin and penicillin resistance are high across Germany.
More than 10% of isolates displayed decreased susceptibility to cephalosporins in 2010 and 2011, mostly to cefixime. 4% of isolates showed a decreased susceptibility to both cephalosporins in 2011. (Table 1) All isolates with decreased susceptibility to cephalosporins also displayed resistance to ciprofloxacin. 
